Metformin: A new treatment option for non-insulin-dependent diabetes mellitus

Journal of Family Practice

Volumn 42, Issue 6, 1996, Pages 612-618

  Goo, Alvin K Y ^a   Carson, Deborah Stier ^b   Bjelajac, Aleksandra ^c  

^a KAISER PERMANENTE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

acidosis, lactic; biguanide; diabetes mellitus, non insulin dependent; hyperinsulinism; Metformin

Indexed keywords

ALCOHOL; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CIMETIDINE; CREATININE; DIURETIC AGENT; GLIBENCLAMIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PLACEBO; RANITIDINE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TRIAMTERENE; TRIMETHOPRIM;

ANOREXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC OBESITY; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG MECHANISM; DRUG POTENTIATION; FLATULENCE; HUMAN; HYPERINSULINEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BIGUANIDES; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SULFONYLUREA COMPOUNDS;

EID: 0029896418     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Bristol-Myers Squibb Co. Glucophage [metformin] package insert. Princeton, NJ: Bristol-Myers Squibb Co, Feb 1995.
2. Bailey C. Biguanides and NIDDM. Diabetes Care 1992; 15:755-72.
3. Baily CJ, Nattrass M. Treatment - metformin. Baillieres Clin Endocrinol Metab 1988; 2:455-76.
4. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49:721-49.
5. Hermann LS, Mclander A. Biguanides: basic aspects and clinical use. In: Alberti KGMM, DcFronzo RA, Keen H, et al, eds. International textbook of diabetes mellitus. New York, NY: John Wiley & Sons, 1992:773-95.
6. Anonymous. Metformin. Phase III drug profiles. Int J Pharm Clin Trials 1994; 4(2): 1-15.
7. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13:696-704.
8. Caspary WF, Creutzfeld W. Analysis of the inhibitory effects of biguanides on glucose absorption: inhibitors of sugar transport. Diabetologia 1971; 7:379-85.
9. Meyer F, Ipaktchi M, Clauser H. Specific inhibition of gluconcogenesis by biguanides. Nature 1967; 213:203-4.
10. Nosadini R, Avogaro A, Trevisan A, Valerio A, Tessari P, Duner H, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10:62-7.
11. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JF. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:550-4.
12. Laakso M, Voutilainen E, Sarlund H, Aror A, Pyorala K, Penttila I. Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetes. Atherosclerosis 1985; 56:271-81.
13. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
14. Griffin BA, Freeman DJ, Tait GW,Thomson J, Caslake MJ, Packard CJ, et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atheroseclerosis 1994; 106:241-53.
15. Reaven GM, Chen Y-DI, Jeppsen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92:141-6.
16. Austin MR, Mykkaneen L, Kuuisisto J, Edwards KL, Nelson C, Haffner SM, Pyrorala K, Laasko M. Prospective study of small LDLs as a risk factor for non-insulin-dependent diabetes mellitus in elderly men and women. Circulation 1996; 92:1770-8.
17. Hermann LS, Schersten B, Bitzen PO. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 1994; 17:1100-9.
18. DeFronzo RA, Barzlai N, Simonson DC, Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73:1294-301.
19. DeFronzo RA, Goodman A, Metformin Investigator Group. Combined metformin/glyburide treatment in NIDDM patients not optimally responding to maximum dose sulfonylurea: results of a multicenter trial. Diabetes 1993; 42(suppl 1):146A.
20. Campbell PJ, Carlson MG. Impact of obesity on insulin action in NIDDM. Diabetes 1993; 42:405-10.
21. Reaven GM. Role of insulin resistance in the pathophysiology of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1993; 9(suppl 1):5S-12S.
22. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly alloted diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin-dependent diabetes followed for three years. BMJ 1995; 310:83-8.
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
24. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Stern MP. Prospective analysis of the insulin resistance syndrome. Diabetes 1992; 41:715-22.
25. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors. The Northern Sweden MONICA populations study. J Intern Med 1993; 234:263-70.
26. Logan RJ, Riemersma RA, Thomson M, et al. Risk factors for ischemic heart disease in normal men aged 40: Edinburgh-Stockholm study. Lancet 1978; 1:949-54.
27. Manolio TA, Savage PJ, Burke GL, Liu KA, Wagenknecht LE, Sidney S, Jacobs DR Jr, et al. Association of tasting insulin with blood pressure in young adults. The CARDIA study. Arteriosclerosis 1990; 10:430-5.
28. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2:154-60.
29. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2:131-41.
30. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor? Diabetes Care 1995; 18:1299-304.
31. McKeigue P, Davey G. Associations between insulin levels and cardiovascular disease are confounded by comorbidity. Diabetes Care 1995; 18:1294-7.
32. Abraira C. VA Cooperative Study on Glycemic Control and Complications in Type II DM [abstract]. Diabetes Care 1994; 43(suppl 1): abstract 187.
33. Abraira C, Colwell JA, Nuttal FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Diabetes Care 1995; 18:1113-23.
34. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, Rosa ND, D'Onofrio F. Metformin for obese, insulin-treated diabetic patients: improvement in glycemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44:107-12.
35. Lankdin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229:181-7.
36. Collier A, Watson HH, Patrick AW, Ludlaw CA, Clarke BF, Capewell S, et al. Effects of' glycacmic control, metfbrmin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin dependent) diabetic patients. Diabete Metab 1989; 15:420-5.
37. DcFronzo RA, Goodman AM, Multicentcr Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:541-9.
38. Klein VV. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Diabete Metab 1991; 17:235-40.
39. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study. Diabetologia 1991; 34:877-90.
40. United Kingdom Prospectives Diabetes Study Group. UK Prospective Diabetes Study 16. Diabetes 1995; 44:1249-58.
41. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11:223-41.
42. 12 in diabetic patients treated with phenformin: a comparison with metformin. BMJ 1973; 882:673-5.
43. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetes: a review of 330 cases. Diabetologia 1978; 14:76-87.
44. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985; 15(suppl):105-11.
45. Canadian Pharmaceutical Association, Krogh CME, ed. Compendium of pharmaceuticals and specialties. 28th ed. Toronto, Canada: CK Productions, 1993:506.
46. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991; 17:224-31.
47. American Diabetes Association. Physician's guide to non-insulin-dependent (type II) diabetes: diagnosis and treatment. 2nd ed. Alexandria, Va: American Diabetes Association, Inc, 1988.
48. Francisco GE, Brooks PJ. Diabetes mellitus. In: Depiro JT, Talbert RL, Hayes PE, et al, eds. Pharmacotherapy. New York, NY: Elsevier, 1992:1121-45.
49. Lebovitz HE, Pasmantier R. Combination insulin-sulfonylurea therapy. Diabetes Care 1990; 13:667-75.
50. Miller JL, Salman K, Shulman LH, Rose LI. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes. Clin Pharmacol Ther 1993; 53:380-4.
51. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44:165-72.
52. Sowers J, Standley P, Ram J. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993; 6:260S-70S.